| Literature DB >> 17173705 |
Rachel A Davey1, Niall C Tebbutt, Jenny M Favaloro, David N O'neal, Derek Rae, Jeffrey D Zajac, James D Best.
Abstract
Severe combined hyperlipidaemia has occasionally been associated with infiltration of tissues in addition to arteries and the skin. We report a woman with Type 2 diabetes mellitus (DM) and severe combined hyperlipidaemia who developed retinal lipid infiltration, resulting in blindness. A 61-year-old woman with a 15-year history of Type 2 DM was admitted following a two-week history of progressive visual loss. Examination identified lipid infiltration into the retina. Phenotypically she had severe combined hyperlipidaemia with elevated IDL cholesterol and a broad beta band on lipoprotein electrophoresis, raising the possibility of familial dysbetalipoproteinaemia. However, gene sequencing analysis indicated that the patient was homozygous for the E3/E3 allele of the ApoE gene with no mutations detected in either the coding region or intron-exon boundaries. Her lipid profile improved following dietary therapy and gemfibrozil treatment, but this had little effect on either her fundal appearances or her visual acuity. Type 2 DM plays a vital role both in allowing expression of severe combined hyperlipoproteinaemia, in addition to serving as a risk factor for complications such as tissue infiltration.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17173705 PMCID: PMC1762005 DOI: 10.1186/1476-511X-5-29
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Figure 1a) Photographs of the patient's eye showing gross exudative and haemorrhagic change, b) Serum lipid profile showing a broad beta band detected in the patient's serum collected on two different days; lane 1: Patient sample #1; lane 2: Patient sample #2; lane 3: control, c) Lipid profile from vitreous material obtained from patient's eye showing faint staining for Intermediate Density Lipoprotein (IDL); lane 1: control; lane 2: Patient sample.
Lipid, Biochemical and Haematological Evaluation.
| Total cholesterol | 10.6 mmol/L | <5.5 mmol/l |
| Total triglyceride | 7.5 mmol/L | <2.0 mmol/1 |
| HDL cholesterol | 0.97 mmol/L | <0.9–2.4 mmol/l |
| LDL cholesterol | 6.6 mmol/L | <3.5 mmol/l |
| VLDL cholesterol | 3.0 mmol/L | <0.5 mmol/l |
| VLDL triglyceride | 5.6 mmol/L | <1.0 mmol/l |
| IDL cholesterol | 2.9 mmol/L | |
| IDL triglyceride | 0.8 mmol/L | |
| Apo A1 | 151 mg/dL | 125–198 mg/dL |
| Apo B | 297 mg/dL | 31–151 mg/dL |
| ApoB/Apo A1 | 1.97 mg/dL | 0.21–0.73 mg/dL |
| ApoE genotyping | E3/E3 | |
| Urea | 9.6 mmol/L | 3.1–8.8 mmol/L |
| Creatinine | 0.13 mmol/L | 0.07–0.11 mmol/L |
| Albumin | 31 g/L | 35–50 g/L |
| 24 hr urinary protein | 3.8 g/day | 0.00–0.08 g/day |
| Thyroid function | Normal | |
| Hb A1C | 7.7% | <7.0% |
| Haemoglobin | 8.2 g/dL | 11.5–16.5 g/dL |
| White cell count | 2.4 × 109/L | 4.0–11.0 × 109/L |
| Platelets | 121 × 109/L | 150–450 × 109/L |
| Auto antibodies | Negative | |
| Rheumatoid factor | Negative | |
| Anti nuclear factor | Negative | |
| Anti neutrophil cytoplasmic antibody | Negative | |